Investor Presentation

August 13, 2026 Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400001 Script Code – 540737 Sub: Investor Presentation. With reference to the captioned subject, we enclose herewith the Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2026. Kindly take the same on your record. Thanking You, Yours faithfully, For Shree Ganesh Remedies Limited Aditya Patel Company Secretary Enc. a/a Investor Presentation Q1FY27 Innovate. React. Transform. Inside the 19 DahejLand Acquisition Setting the Stage for Large Scale Projects Forward 20 Driving Innovation Through Strategic R&D Investments Presentation Looking 21 State-of-the-Art R&D Infrastructure Statement 22 State-of-the-Art Pilot Infrastructure In so far as forecasts or 23 Accreditations that Speak to Our Comprehensive Standards expectations are 24 Driving Innovation and Growth expressed in this Quarterly Highlights presentation or where 25 Ensuring Health and Safety our statements concern 04 Management Commentary 26 Protecting the Environment With Sustainable Practices the future, these 05 P&L Summary forecasts, expectations or statements may 06 Balance Sheet Summary involve known or 07 Cash Flow Summary unknown risks and uncertainties. Actual results or developments Financial Highlights may vary, depending on changes in the 28 5 Year Summary operating environment. About the Business Shree Ganesh Remedies 29 Key Ratios 09 Excellence in Complex Chemistry Limited does not 30 P&L Summary assume an obligation to 10 Unparalleled Expertise in Advanced Chemical Synthesis update the forecasts, 31 Balance Sheet Summary 12 Unmatched Technology Prowess In Complex Chemical Reactions expectations or 32 Cash Flow Summary statements contained in 13 Tailored Solutions Through Mastered Chemistry and Technology this presentation. 14 Strategic Product Selection Criteria 15 Our Evolving Business Model 16 Collaborating With Industry Leaders Investment Merits 17 AnkleshwarSite Expansion Fuelling Our Growth Strategy 34 Investment Case 18 Infrastructure at Ankleshwar Site Shree Ganesh Remedies Limited Quarterly Highlights Management Commentary 04 P&L Summary 05 Balance Sheet Summary 06 Cash Flow Summary 07 QUARTERLY HIGHLIGHTS Management Commentary Q1FY27 has been a challenging quarter for the Company. On the CRAMS front, our engagements in South-East Asia European demand has continued to remain subdued, with continue to progress in line with our expectations and a meaningful number of customers deferring orders timelines, and we anticipate these projects beginning to amidst the ongoing geopolitical uncertainty and contribute to revenues from H2FY27. considerable volatility in raw material markets. This has had a direct bearing on our topline and profitability for the Given the unexpected persistence of geopolitical quarter, and I would note that the subdued demand headwinds, customer caution, and a visibly softer first half, environment has persisted into the early part of Q2FY27 as we believe it is appropriate to moderate our earlier well. guidance of FY27 being a year of non-linear growth. The CRAMS pipeline remains firmly on track, Block 7 remains Additionally, during the quarter, our marketing and on course for commissioning, and the strategic direction of manufacturing agreement with one of our EU distributors the business has not changed. The strategies we have laid reached its automatic termination owing to non- out are being executed with the same rigourand intent. performance as per the agreed terms of the commercial What we are navigating is a timing issue. The foundations agreement. This opens the way for the Company to we have built over the past year or more remain intact, engage directly with customers, giving us greater control and we are confident that the second half of FY27 will over these relationships and the opportunity to develop reflect a meaningful improvement in performance as these them on our own terms. We expect this transition to take a catalysts progressively come online. couple of quarters before volumes are meaningfully restored, and we remain confident of returning to our prior We remain steadfast in our belief that patient, disciplined run-rate levels in the second half of the financial year. execution on the right strategic priorities will deliver a stronger and more profitable business over the medium to long term. Gunjan Kothia Promoter, Head of Business Development & Innovation Shree Ganesh Remedies Limited QUARTERLY HIGHLIGHTS P&L Summary -42% -54% -68% YoY Change Revenue EBITDA PAT YoY QoQ PARTICULARS Q1FY26 Q4FY26 Q1FY27 (₹ IN CRORES) Change Change Revenue from Operations 24.67 33.20 14.36 -42% -57% Total Income 25.33 34.22 15.30 -40% -55% Operating Expenses 17.37 21.87 11.01 -37% -50% EBITDA (Excluding OI & EI) 7.30 11.37 3.35 -54% -71% EBITDA % 29.6% 34.3% 23.3% -624 bps -1,092 bps Finance Cost 0.94 0.88 0.32 -66% -64% Depreciation & Ammortization 2.42 2.80 2.44 1% -13% PBT 4.60 8.72 1.53 -67% -82% PAT 3.45 6.27 1.12 -68% -82% EPS (₹) 2.69 4.88 0.87 -68% -82% Shree Ganesh Remedies Limited QUARTERLY HIGHLIGHTS Balance Sheet Summary PARTICULARS FY25 FY26 (₹ IN CRORES) Shareholders' Funds 145.19 163.02 Non-Current Liabilities 30.60 23.03 Long Term Borrowings 29.48 21.25 Current Liabilities 16.18 21.69 Short Term Borrowings 8.76 9.42 Trade Payables 5.97 9.44 Total Equity and Liabilities 191.98 207.74 Non-Current Assets 114.45 121.91 Tangible Assets 57.91 68.08 CWIP 8.34 12.38 Current Assets 77.53 85.83 Inventories 22.02 24.01 Trade Receivables 22.27 32.57 Cash & Bank Balances 9.99 13.45 Investments 18.26 12.45 Total Assets 191.98 207.74 Shree Ganesh Remedies Limited QUARTERLY HIGHLIGHTS Cash Flow Summary PARTICULARS FY25 FY26 (₹ IN CRORES) Cash from Operating Activities 30.66 23.75 Cash from Investing Activities -35.66 -9.89 Cash from Financing Activities -1.06 -11.70 Net Cash Flow -6.05 2.17 Cash at the Beginning of Year 15.78 9.90 Cash at the End of Year 9.90 13.36 Shree Ganesh Remedies Limited About the Business Excellence in Complex Chemistry 09 Unparalleled Expertise in Advanced Chemical Synthesis 10 Unmatched Technology Prowess In Complex Chemical Reactions 12 Tailored Solutions Through Mastered Chemistry and Technology 13 Strategic Product Selection Criteria 14 Our Evolving Business Model 15 Collaborating With Industry Leaders 16 AnkleshwarSite Expansion Fuelling Our Growth Strategy 17 Infrastructure at AnkleshwarSite 18 DahejLand Acquisition Setting the Stage for Large Scale Projects 19 Driving Innovation Through Strategic R&D Investments 20 State-of-the-Art R&D Infrastructure 21 State-of-the-Art Pilot Infrastructure 22 Accreditations that Speak to Our Comprehensive Standards 23 Driving Innovation and Growth 24 Ensuring Health and Safety 25 Protecting the Environment With Sustainable Practices 26 ABOUT THE COMPANY Excellence in Complex Chemistry Established Expertise Strategic Expansions Over 20 years of excellence in chemical Continuous investments in new manufacturing manufacturing, specialising in pharmaceutical blocks and R&D centers to enhance production intermediates and speciality chemicals. capacity and innovation. Global Reach Trusted Partner Serving over 20 countries, including key Trusted partner for leading global companies, markets in the EU and the US, with a offering reliable and high-quality custom robust export portfolio. manufacturing solutions. Innovative Capabilities Sustainable Practices Equipped with state-of-the-art R&D Committed to environmental sustainability with facility, enabling complex chemical ISO 14001, certification and initiatives in solar synthesis and innovation. energy and waste recycling. Shree Ganesh Remedies Limited ABOUT THE COMPANY Unparalleled Core Strengths in Mastered Chemistries Our company excels in the following core chemistries, Expertise in with dedicated manufacturing blocks for each: Advanced 1. Halogenation • Chlorination: Using [Showing first 8,000 characters — download PDF for full document]